Stockscreener 앱 받기
4.27
0.70%
-0.03
전일 마감가:
$4.30
열려 있는:
$4.4
하루 거래량:
21,489
Relative Volume:
0.03
시가총액:
$4.98M
수익:
$1,000
순이익/손실:
$-11.39M
주가수익비율:
-0.139
EPS:
-30.7182
순현금흐름:
$-7.26M
1주 성능:
+1.43%
1개월 성능:
-29.54%
6개월 성능:
-47.12%
1년 성능:
-89.46%
1일 변동 폭
$4.18
$4.50
1주일 범위
$4.18
$4.7479
52주 변동 폭
$3.1829
$71.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
명칭
Ernexa Therapeutics Inc
전화
(617) 798-6700
주소
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
4.27 | 5.16M | 1,000 | -11.39M | -7.26M | -30.72 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ernexa Therapeutics Inc 주식(ERNA)의 최신 뉴스
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Announces Appointment of David Polinsky to Board of Directors - marketscreener.com
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportMarket Profile - dars.gov.et
Ernexa Therapeutics Inc. Revenue Breakdown – BOATS:ERNAW - TradingView
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance UK
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa Therapeutics advances ERNA-101, a cell t... - Pluang
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 - GlobeNewswire
Tumors cleared in about two-thirds of animals in ERNA-101 study - Stock Titan
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies - Yahoo Finance
Ernexa's Innovative Approach to Cancer Treatment - Intellectia AI
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy - Sahm
ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial - StocksToTrade
ERNA stock jumps as investors appear to refocus on ERNA-101 clinical milestones - Quiver Quantitative
ERNA Stock Pops As Ernexa Flags Progress Toward First Trials - StocksToTrade
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Yahoo Finance
ERNA Stock Draws Trader Attention As Biotech Maps 2026–2027 Trial Roadmap - timothysykes.com
Wednesday's pre-market session: top gainers and losers - ChartMill
Ernexa's ERNA-101 combo clears tumors and boosts survival in ovarian cancer preclinical study. - Pluang
Ernexa reports positive preclinical data for cancer therapy By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission - Quiver Quantitative
Ernexa Therapeutics stock surges 30% on preclinical data By Investing.com - Investing.com Canada
Ernexa Therapeutics Receives Independent Validation of - GlobeNewswire
Ernexa plans IND filing for ovarian cancer therapy ERNA-101 By Investing.com - Investing.com Canada
Ernexa Therapeutics plans first-in-human trial of ERNA-101 for ovarian cancer in late 2026 - Pluang
Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade - Stock Titan
Ernexa Therapeutics Inc. Q3 2023 Earnings: Pre-Revenue Biotech Reports Net Loss Amid Pipeline ProgressAnalyst Drop Coverage - po-news-eg.net
Eterna Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosures - TipRanks
Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan - Stock Titan
ERNA Q3 2023 Earnings: Reported Loss per Share of -$1.03, Stock Rises $1.37Revenue Growth Outlook - dars.gov.et
ERNA stock shoots up 140% in a month: Here's what you should know - MSN
Ernexa Therapeutics (ERNA) Posts Modest Gain as Stock Holds Above Key SupportInsider Selling Alerts - dars.gov.et
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.06 – A Waiting Game for CatalystsUnusual Call Volume - dars.gov.et
Price to sales forward of Ernexa Therapeutics Inc. – BOATS:ERNAW - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – BOATS:ERNAW - TradingView
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Eterna Therapeutics announces finance leadership transition and search - TipRanks
Sandra Gurrola to Resign as Ernexa's Senior VP of Finance, Effective July 3, 2026 - TradingView
Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition - Stock Titan
Ernexa Therapeutics (ERNA) Slides 12% as Selling Pressure IntensifiesBreak of Structure - dars.gov.et
Ernexa Therapeutics Surges 20.6%: Momentum Builds for ERNA Stock After BreakoutVolume Nodes - dars.gov.et
Ernexa Therapeutics Inc (ERNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):